{"url_path":"/sec/pmi/8-k/2026-06-24/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/2030617/0001437749-26-021504-index.html","accession_number":"0001437749-26-021504","cik":"0002030617","ticker":"PMI","issuer_name":"Picard Medical, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2030617/0001437749-26-021504-index.html","primary_entity_key":"0002030617","primary_entity_name":"Picard Medical, Inc."},"word_count":111,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure.**\n\n \n\nOn June 24, 2026, Picard Medical, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the leadership transition. A copy of the Press Release is furnished as Exhibit 99.1 and incorporated by reference herein.\n\n \n\nThe information in this report and the exhibits attached hereto shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing."}